GlaxoSmithKline PLC (NYSE:GSK)‘s stock had its “neutral” rating reissued by equities research analysts at Citigroup Inc. in a report released on Thursday.

Other equities analysts have also recently issued reports about the stock. ValuEngine cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, May 31st. BidaskClub cut shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday. BNP Paribas raised shares of GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating and lowered their price target for the company from $45.58 to $37.20 in a report on Wednesday, April 5th. Finally, Exane BNP Paribas raised shares of GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating in a report on Wednesday, April 5th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $46.00.

Shares of GlaxoSmithKline PLC (NYSE:GSK) traded down 0.2531% on Thursday, reaching $40.7466. 1,951,243 shares of the company’s stock traded hands. The company’s 50-day moving average is $43.02 and its 200-day moving average is $41.78. The firm has a market capitalization of $99.54 billion, a P/E ratio of 45.5779 and a beta of 1.04. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $45.58.

GlaxoSmithKline PLC (NYSE:GSK) last released its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.02. The firm had revenue of $9.36 billion during the quarter, compared to analysts’ expectations of $9.52 billion. GlaxoSmithKline PLC had a net margin of 5.48% and a return on equity of 113.31%. Equities research analysts anticipate that GlaxoSmithKline PLC will post $2.86 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “GlaxoSmithKline PLC’s (NYSE:GSK) “Neutral” Rating Reiterated at Citigroup Inc.” was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/27/glaxosmithkline-plcs-nysegsk-neutral-rating-reiterated-at-citigroup-inc.html.

A number of large investors have recently modified their holdings of GSK. Bronfman E.L. Rothschild L.P. raised its stake in shares of GlaxoSmithKline PLC by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock worth $102,000 after buying an additional 753 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in shares of GlaxoSmithKline PLC by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 2,359 shares in the last quarter. Proficio Capital Partners LLC raised its stake in shares of GlaxoSmithKline PLC by 233.0% in the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after buying an additional 1,990 shares in the last quarter. Heritage Trust Co bought a new stake in shares of GlaxoSmithKline PLC during the first quarter worth approximately $123,000. Finally, Westwood Holdings Group Inc. raised its stake in shares of GlaxoSmithKline PLC by 15.7% in the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after buying an additional 400 shares in the last quarter. 8.98% of the stock is currently owned by hedge funds and other institutional investors.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.